Related Experiment Video
Updated: Oct 15, 2025

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p
Suzanne Faure-Dupuy1,2, Tobias Riedl1,3, Maude Rolland4
1Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Insights
Immune-mediated APOBEC3B induction, regulated by NF-κB and miR-138-5p, effectively reduces hepatitis B virus cccDNA. Inhibiting miR-138-5p may enhance this antiviral effect for new HBV therapies.
Area of Science:
- Hepatology and Virology
- Immunology
- Molecular Biology
Background:
- Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) persistence is a major barrier to chronic infection cure.
- Immune-mediated induction of cytidine deaminase APOBEC3B (A3B) has shown potential in reducing HBV cccDNA.
- Understanding the regulatory mechanisms of A3B induction is crucial for developing effective antiviral strategies.
Purpose of the Study:
- To elucidate the signaling pathways and regulatory mechanisms governing A3B induction.
- To investigate the role of NF-κB and microRNA-138-5p (miR-138-5p) in A3B-mediated HBV control.
- To evaluate the therapeutic potential of modulating A3B expression for HBV treatment.
Main Methods:
- Utilized differentiated HepaRG cells and primary human hepatocytes with or without HBV infection.
- Employed knockdown of NF-κB signaling components, siRNA/miRNA transfections, and treatment with lymphotoxin beta receptor (LTβR)-agonist (BS1).
- Applied a comprehensive suite of molecular analyses including qPCR, immunoblotting, sequencing, and mass spectrometry.
Main Results:
- Both canonical and non-canonical NF-κB pathways are essential for A3B induction and anti-HBV activity.
- A3B expression is post-transcriptionally regulated by miR-138-5p, which promotes A3B mRNA decay; its overexpression reduced A3B levels and antiviral effects.
- LTβR-agonist treatment significantly reduced cccDNA by 80% without damaging key host genes, independent of cccDNA transcriptional activity.
Conclusions:
- APOBEC3B is the first described enzyme capable of degrading both transcriptionally active and inactive HBV cccDNA.
- Inhibiting miR-138-5p should be considered in combination therapies for HBV, particularly when leveraging immune-mediated A3B induction.
- A3B-mediated cccDNA decay presents a promising therapeutic avenue for chronic HBV infection.
Background & Aims:
Immune-mediated induction of cytidine deaminase APOBEC3B (A3B) expression leads to HBV covalently closed circular DNA (cccDNA) decay. Here, we aimed to decipher the signalling pathway(s) and regulatory mechanism(s) involved in A3B induction and related HBV control.
Methods:
Differentiated HepaRG cells (dHepaRG) knocked-down for NF-κB signalling components, transfected with siRNA or micro RNAs (miRNA), and primary human hepatocytes ± HBV or HBVΔX or HBV-RFP, were treated with lymphotoxin beta receptor (LTβR)-agonist (BS1). The biological outcomes were analysed by reverse transcriptase-qPCR, immunoblotting, luciferase activity, chromatin immune precipitation, electrophoretic mobility-shift assay, targeted-bisulfite-, miRNA-, RNA-, genome-sequencing, and mass-spectrometry.
Results:
We found that canonical and non-canonical NF-κB signalling pathways are mandatory for A3B induction and anti-HBV effects. The degree of immune-mediated A3B production is independent of A3B promoter demethylation but is controlled post-transcriptionally by the miRNA 138-5p expression (hsa-miR-138-5p), promoting A3B mRNA decay. Hsa-miR-138-5p over-expression reduced A3B levels and its antiviral effects. Of note, established infection inhibited BS1-induced A3B expression through epigenetic modulation of A3B promoter. Twelve days of treatment with a LTβR-specific agonist BS1 is sufficient to reduce the cccDNA pool by 80% without inducing significant damages to a subset of cancer-related host genes. Interestingly, the A3B-mediated effect on HBV is independent of the transcriptional activity of cccDNA as well as on rcDNA synthesis.
Conclusions:
Altogether, A3B represents the only described enzyme to target both transcriptionally active and inactive cccDNA. Thus, inhibiting hsa-miR-138-5p expression should be considered in the combinatorial design of new therapies against HBV, especially in the context of immune-mediated A3B induction.
Lay Summary:
Immune-mediated induction of cytidine deaminase APOBEC3B is transcriptionally regulated by NF-κB signalling and post-transcriptionally downregulated by hsa-miR-138-5p expression, leading to cccDNA decay. Timely controlled APOBEC3B-mediated cccDNA decay occurs independently of cccDNA transcriptional activity and without damage to a subset of cancer-related genes. Thus, APOBEC3B-mediated cccDNA decay could offer an efficient therapeutic alternative to target hepatitis B virus chronic infection.
More Related Videos
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Co-activators and Co-repressors
Regulation of Nuclear Protein Sorting
Master Transcription Regulators
Abnormal Proliferation
The Intrinsic Apoptotic Pathway

